-
Highlights from our recent and ongoing HEOR work
This page features materials on Analysis Group’s recent work and thought leadership in HEOR. For a deeper look at our HEOR, Epidemiology & Market Access practice, please click here.
ISPOR Europe 2024
In addition to several research posters, Analysis Group is proud to present the educational symposium “Advancing Evidence-Based Medicine With Generative AI (GenAI)” at ISPOR Europe 2024. Presenters, including Managing Principal Eric Q. Wu, Principal Jimmy Royer, and Vice President Rajeev Ayyagari, will explore the frontiers in GenAI, discuss key developments and challenges, and present examples of GenAI’s applications in HEOR and real-world research. Among these examples is Analysis Group’s own proprietary GenAI platform, AGHealth.ai, which excels in text classification, research summarization, and automated data analysis.
Eric Q. Wu: Managing Principal, Analysis Group
Jimmy Royer: Principal, Analysis Group
Rajeev Ayyagari: Vice President, Analysis Group
Read more about Analysis Group’s symposium and posters at ISPOR Europe 2024
Review a compendium of the firm’s published HEOR research and presentations
Examples of our work
- Contribution of Hyperkalemia to Risks of CKD Progression and Mortality Explored in Analysis Group Coauthored Study
- Factors Contributing to Delays in Blood Thinner Prescriptions Identified in Analysis Group Study
- New Method for Measurement of Biopharmaceutical R&D Investment Detailed by Analysis Group Coauthors in Nature Reviews Drug Discovery Article
- Analysis Group Coauthors Examine the Impact of In-Office Dispensing Services on Prostate Cancer Patients
- Analysis Group Team Conducts Discrete Choice Experiment Survey to Quantify Treatment Preferences in Patients with Moderate-to-Severe Atopic Dermatitis
- Analysis Group Researchers Coauthor First Large-Scale US Study on Incidence of Pneumococcal Disease in Children 0–2 Years Old
- Analysis Group Team Coauthors Study on Health Care Resource Utilization and Costs in US Patients with GERD, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia
- The Global Carbon Footprint of Asthma Inhalers: Policy Shifts Can Reduce Emissions, Analysis Group Study Finds
- Health Care Resource Utilization Study Coauthored by Analysis Group Is First to Describe Economic Burden of MDSI
- The Economic Burden of Adults with Major Depressive Disorder in the United States
- Analysis Group Collaborates with William Osler Health System and Janssen to Estimate Cost Savings to the Canadian Health Care System of Using Next-Generation Sequencing Testing in Metastatic Non-Small Cell Lung Cancer
- Analysis Group Team Conducts One of First Studies to Focus on Clinical and Economic Burden of US Patients with Multiple Myeloma and Renal Impairment
- Analysis Group and Pfizer Present Final Data on COVID-19 Vaccine Safety Surveillance Program of US Veterans Health Administration Patients
- Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
- Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
- Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
- Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States
- Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison
- Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
- Artificial Intelligence and Real-World Evidence in Oncology Research: A Q&A with Eric Wu
- Analysis Group Researchers Identify Neighborhood Characteristics That May Predict Psoriasis in Quebec, Canada
- Analysis Group Researchers Develop a Novel Framework to Help Clinicians Predict the Likelihood of Antibiotic-Resistant Bacteria in Patients with Uncomplicated Urinary Tract Infections
- High Power and High Stakes: A Q&A on Machine Learning in Diagnostics
- Pair of Digital Health Research Papers Coauthored by Analysis Group Demonstrate Promises of Wearables to Generate Reliable Site-less Patient-Reported Outcomes in Rheumatoid Arthritis
- Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria
- Profiling Disease and Economic Burden in CRSwNP Using Machine Learning
- Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning Approach
- Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data
- Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
- Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
- Analysis Group Researchers Identify Novel Approach for Assessing Real-World Treatment Effectiveness in Patients with IBS-D
- Analysis Group Health Care Researchers Pioneer New Method for Generating Real-World Data
- Shared Learning Without Waiting for Shared Data: Using Federated Analytics for Health Care Research Across Multiple Institutions and Countries
- A New “Gold Standard”? How Digital Health Technologies Can Be Used to Monitor Patient Progress
- Quantitative Approaches to Stress-Testing Scientific Claims in Health Care
- Analysis Group Announces Real-World Evidence Study Supported Blueprint Medicines’ Label Expansion of AYVAKYT® (avapritinib) to Advanced Systemic Mastocytosis in the EU
- Study by Analysis Group and AstraZeneca Researchers Fills Real-World Data Gap for Providers Treating Severe Asthma Sufferers
- Using Real-World Data to Understand Treatment Patterns and Outcomes of Blood Disease Patients in China
- Analysis Group Coauthors Explore Novel Method for Assessing Real-World Data on Longitudinal Patient-Reported Outcomes
- Contribution of Hyperkalemia to Risks of CKD Progression and Mortality Explored in Analysis Group Coauthored Study
AG Feature
This feature was published in November 2024.